New pill aims to keep aggressive lymphoma at bay after initial treatment
NCT ID NCT07293403
Summary
This study tests whether taking duvelisib pills can help prevent cancer from returning in patients with peripheral T-cell lymphoma who have achieved remission after initial chemotherapy. The trial is for patients who have responded well to first treatment but cannot or choose not to undergo stem cell transplant. Participants will take duvelisib twice daily for up to two years while researchers monitor whether the cancer stays away and how well patients tolerate the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.